Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, fol...
Lorlatinib is indicated for the treatment of adult patients with ALK-positive metastatic non-small cell lung cancer (NSCLC). In the EU, it is indicated for the treatment of adult patients with ALK-positive advanced NSCLC not previously treated with an ALK inhibitor, or whose disease has progressed after using either alectinib or ceritinib, or crizotinib and ...
National Cancer Center, Goyang-Si, Gyeonggi-do, Korea, Republic of
EmpiraMed, Inc., Maynard, Massachusetts, United States
Anaheim Clinical Trials, LLC, Anaheim, California, United States
Prism Clinical Research, LLC, Saint Paul, Minnesota, United States
UOC Ematologia, Ospedale S. Eugenio, Roma, Italy
Asst-Monza, Monza, Italy/MB, Italy
IRCCS - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)- Oncologia Medica, Meldola, Forlรฌ- Cesena, Italy
Istituto Toscano Tumori Ospedale San Donato- U.O.C. di Oncologia Medica Dipartimento di Oncologia USL-8, Arezzo, Italy
Azienda Ospedaliera di Rilievo Nazionale "S.G. Moscati", Avellino, Italy
Memorial Cancer Institute at Memorial Hospital West, Pembroke Pines, Florida, United States
Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
The Ohio State University, Columbus, Ohio, United States
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
Henry Ford Health Saint John Hospital, Detroit, Michigan, United States
Children's Hospital of Alabama, Birmingham, Alabama, United States
Royal Marsden Hospital, Sutton, Surrey, United Kingdom
Cook Children's Healthcare System, Fort Worth, Texas, United States
Children's Healthcare of Atlanta, Atlanta, Georgia, United States
The William P. Beetham Eye Institute, Joslin Diabetes Center, Boston, Massachusetts, United States
Ophthalmic Consultants of Boston Inc, Boston, Massachusetts, United States
University of Washington Medical Center, Seattle, Washington, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.